Aurobindo gets USFDA Approval for Trandolapril Tablets

Aurobindo Pharma Ltd has announced that the Company has received approval from the USFDA for Trandolapril Tablets 1 mg, 2 mg & 4 mg. Trandolapril is the Generic equivalent of Abbott's Mavik® Tablets, indicated for the treatment of hypertension.

This is the fourth Anti hypertensive (Medicines regulating blood pressure) of the Company bagging USFDA's nod. Trandolopril is an ACE inhibitor, and amongst the class, has a longer half-life hence dosed once a day. Trandolopril is also employed in combination with diuretics or other calcium channel blockers due to its beneficial synergy. It is a better choice in diabetic hypertensives as it helps in slowing down the onset of nephropathy besides primary role of regulating blood pressure.

Trandolopril tablets enjoy a market share of around 50 million dollars currently in the USA.

The stock was trading at Rs.749.50, down by Rs.2.65 or 0.35%. The stock hit an intraday high of Rs.764 and low of Rs.749. The total traded quantity was 51371 compared to 2 week average of 220958.

Source : Equity Bulls

Keywords